The first clinical trial using LNP-encapsulated CRISPR-Cas9 was initiated in 2020 and targeted the TTR gene in hepatocytes for the treatment of transthyretin amyloidosis with cardiomyopathy. The gene discussed is TTR; the disease is cardiomyopathy.